PodParley PodParley
PodParley
Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials - report from ASH 2025 episode artwork

EPISODE · Jan 7, 2026 · 6 MIN

Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials - report from ASH 2025

from Medical Digest & Congress Report · host Medical Congress News

Jesse Tettero discusses the results from the HARMONY Alliance study at the American Society of Hematology's 67th Annual Meeting.Video: https://medicaldigest.org/scientific-contents/interview:validation-measurable-residual-disease-surrogate-endpoint-acute-myeloid-leukemia-harmony-alliance-study-european-randomized-trials

Episode metadata supplied by the publisher feed · Published Jan 7, 2026

Embed this episode

NOW PLAYING

Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials - report from ASH 2025

0:00 6:06

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 6 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on January 7, 2026.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!